Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis.
BACKGROUND
The percentage of time within the target INR range 2.0 to 3.0 (TTR) in patients treated with vitamin K antagonists varies considerably among efficacy-studies of novel anticoagulants. In order to properly asses the quality of anticoagulant control in upcoming cost-effectiveness studies and real life registries this systematic review reports a benchmark of TTR for different treatment durations in patients with venous thromboembolism and discusses ways to calculate TTR.


METHODS
Medline and Embase were searched for studies published between January 1990 and May 2012. Randomized controlled trials and cohort studies reporting the TTR in patients with objectively confirmed venous thromboembolism treated with vitamin K antagonists (VKA) were eligible. Duplicate reports, studies only reporting INR during initial treatment or with VKA treatment less than 3 months were excluded. Three authors assessed trials for inclusion and extracted data independently. Discrepancies were resolved by discussion between the reviewers. A meta-analysis was performed by calculating a weighted mean, based on the number of participants in each included study, for each time-period in which the TTR was measured since the confirmation of the diagnosis of VTE.


RESULTS
Forty studies were included (26064 patients). The weighted means of TTR were 54.0% in the first month since the start of treatment, 55.6% in months 1 to 3, 60.0% in months 2 to 3, 60.0% in the months 1 to 6+ and 75.2% in months 4 to 12+. Five studies reported TTR in classes. The INR in these studies was ≥ 67% of time in therapeutic range in 72.0% of the patients.


CONCLUSIONS
Reported quality of VKA treatment is highly dependent on the time-period since the start of treatment, with TTR ranging from approximately 56% in studies including the 1(st) month to 75% in studies excluding the first 3 months.
Department of Family Medicine, School for Public Health and Primary Care and Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre, Maastricht, The Netherlands. petra.erkens@maastrichtuniversity.nl
Petra M G
PM
Erkens
Hugo
H
ten Cate
Harry R
HR
Büller
Martin H
MH
Prins
D000925:Anticoagulants / Q000191:economics* / Q000494:pharmacology / Q000627:therapeutic use; D019985:Benchmarking; D003362:Cost-Benefit Analysis; D016206:Databases, Bibliographic; D019468:Disease Management; D006801:Humans; D019934:International Normalized Ratio; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000188:drug therapy* / Q000191:economics; D014812:Vitamin K / Q000037:antagonists & inhibitors
D000925:Anticoagulants; D014812:Vitamin K